Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2001
11/01/2001WO2001029046A3 A salt of morphine
11/01/2001WO2001029015A3 Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
11/01/2001WO2001012233A3 Sustained release formulation of a peptide
11/01/2001US20010037026 Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst
11/01/2001US20010037023 Alkyl pyrimidines substituted piperidine derivatives are used as tachykinin antagonsit, useful in the treatment of pain, depression, anxiety, panic, schizophrenia, neuralgia, addiction disorder, inflammation, and neurological disorders
11/01/2001US20010037021 11-keto-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo(c,f)( 1,2)thiazepine is reacted with sodium borohydride in presence of chlorinated solvent and a catalyst to form alcohol, then chlorinating to form chloride, finally forming a salt
11/01/2001US20010036956 Estrogen receptor modulators
11/01/2001US20010036953 Pyridyl-1,2,5-thiadiazole derivatives
11/01/2001US20010036950 Potassium channel openers
11/01/2001US20010036949 Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
11/01/2001US20010036946 Antiinflammatory agents
11/01/2001US20010036945 Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands
11/01/2001US20010036943 Mixture of analgesic and carrier
11/01/2001US20010036942 Nervous system disorders
11/01/2001US20010036500 For enriching foods or beverages, anemia treatment
11/01/2001US20010036484 Improving blood flow circulation by administration of the combination of medicinal plants Panax ginseng and Ginkgo biloba or extracts thereof
11/01/2001US20010036477 Oral administering
11/01/2001US20010036454 Transfection of lung tissue
11/01/2001CA2683045A1 Diazabicyclic central nervous system active agents
11/01/2001CA2407449A1 Novel compounds
11/01/2001CA2407445A1 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo¬3,4-b|-pyridines as cyclin dependent kinase inhibitors
11/01/2001CA2407084A1 Isolated human transporter proteins, nucleic acids and uses thereof
11/01/2001CA2406982A1 Zolpidem hemitartrate
11/01/2001CA2406855A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001CA2406725A1 Edg8 receptor, its preparation and use
11/01/2001CA2406639A1 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001CA2406272A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists
11/01/2001CA2406264A1 Protein phosphatases
11/01/2001CA2406073A1 A protein kinase c variant to alter memory
11/01/2001CA2405170A1 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
11/01/2001CA2405025A1 (2-aminoethyl) oxime derivatives for the treatment of depression
11/01/2001CA2404898A1 Ultrashort acting hypnotic barbiturates
11/01/2001CA2402808A1 Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines
11/01/2001CA2372673A1 Cyclic amidine compounds
11/01/2001CA2365320A1 Novel heterocyclic compounds
10/2001
10/31/2001EP1149903A1 ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
10/31/2001EP1149159A1 Human t cell effectors expressing cd86 molecule and therapeutic use thereof
10/31/2001EP1149116A1 Process for the production of multiple cross-linked hyaluronic acid derivatives
10/31/2001EP1149114A2 Polypeptides involved in immune response
10/31/2001EP1149113A1 Use of agonists or antagonists of mip-3a in therapy
10/31/2001EP1149105A1 4,5-pyrazinoxindoles as protein kinase inhibitors
10/31/2001EP1149102A1 Triazolo-pyridazine derivatives as ligands for gaba receptors
10/31/2001EP1149101A1 4-OXO-3,5-DIHYDRO-4$i(H)-PYRIDAZINO 4,5-$i(b)]INDOLE-1-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE
10/31/2001EP1149091A1 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
10/31/2001EP1149087A1 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
10/31/2001EP1149085A1 Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
10/31/2001EP1149083A1 Morpholinobenzamide salts
10/31/2001EP1149079A1 Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same
10/31/2001EP1149076A1 O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically acceptable salts and process for preparing the same
10/31/2001EP1149074A1 Acetylenic sulfonamide thiol tace inhibitors
10/31/2001EP1149063A2 Ureido-thiobutyric acid derivatives as ppar-agonists
10/31/2001EP1148902A1 Method of enhancing needleless transdermal powdered drug delivery
10/31/2001EP1148889A2 Method of treating demyelinating inflammatory disease using ccr1 antagonists
10/31/2001EP1148887A2 Regulation of anaesthesia
10/31/2001EP1148881A1 USE OF PYRIDAZINO 4,5-$i(b)]INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS
10/31/2001EP1148874A1 Use of anticonvulsant derivatives for treating bulimia nervosa
10/31/2001EP1148873A2 Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
10/31/2001EP1148791A1 Protein material for slow digestion and its use
10/31/2001EP1044201A4 3-substituted adenines via2-thioxanthines
10/31/2001EP0888286B1 Novel substituted cyclic amino acids as pharmaceutical agents
10/31/2001EP0876356B1 Use of tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof
10/31/2001EP0833652A4 Novel kappa receptor selective opioid peptides
10/31/2001EP0820455B1 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES
10/31/2001EP0787131B1 Benzenesulphonamide derivatives as bradykinine antagonists
10/31/2001EP0767782B1 Aryl and heteroaryl alkoxynaphthalene derivatives
10/31/2001EP0737192B1 Substituted morpholine derivatives and their use as therapeutic agents
10/31/2001EP0723454B1 Novel tripeptides useful in immune and cns therapy
10/31/2001EP0717620B1 Substituted 2-aminotetralins
10/31/2001DE10021246A1 New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
10/31/2001CN1320117A 2-substituted heterocyclic sulfonamides
10/31/2001CN1320116A Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals
10/31/2001CN1320039A Reduction of oxidative stress factors
10/31/2001CN1320038A 2-methyl-thieno-benzodiazepine formulation
10/31/2001CN1320034A Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the manufacturing of medicament for intraspinal, intrathecal or epidural edministration
10/31/2001CN1319593A Process for prpearing 11-amino-3-chlorine-6,11-dihydrogen-5,5-dioxo-6-methyl-dibenzo [c,f][1,2] thiazine and application of synthetic tianeptine
10/31/2001CN1319423A Nerve regenerant and productive method and use
10/31/2001CN1073996C Crystalline form of dihydro-2,3-benzodiazepine derivative
10/31/2001CN1073995C Physical form of dihydro-2,3-benzodiazepine derivative
10/31/2001CN1073988C Substituted N-heteroaroylguanidin, preparation, pharmaceutical application and medicine containg same
10/31/2001CN1073855C 芦荟组合物 Aloe composition
10/30/2001US6310226 Vitamin D analogues
10/30/2001US6310213 Good affitity to the nmda receptor and they are therefore useful in the treatment of neurodegenerative diseases
10/30/2001US6310208 Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
10/30/2001US6310203 Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands
10/30/2001US6310101 Administering to the mammal suffering from panic disorder an effective amount of a venlafaxine derivative
10/30/2001US6310099 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
10/30/2001US6310092 Treating systemic lupus, multiple sclerosis, rheumatoid arthritis, septic shock, erythema nodosum leprosy, septicemia, uveitis, adult respiratory distress syndrome or inflammatory bowel disease
10/30/2001US6310088 Treating condition associated with matrix metalloproteinases or mediated by tumor necrosis factor-alpha or enzymes involved in shedding l-selectin, cd23, tumor necrosis factor receptors, interleukin-6 receptors or interleukin-1 receptors
10/30/2001US6310079 Non-steroidal antiinflammatory agents
10/30/2001US6310074 Substituted dimeric compounds
10/30/2001US6310072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist
10/30/2001US6310068 Benzonitriles and benzofluorides
10/30/2001US6310063 Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
10/30/2001US6310061 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
10/30/2001US6310059 Constrained fused ring derivatives of piperidine or piperazine linked to hydrophobic substituents which enhance calcium channel blocking activity; combinatorial libraries for drug screening
10/30/2001US6310052 Nitrate esters and their use for neurological conditions
10/30/2001US6309876 Expression vector for propagation of cells in nervous system; for treating nervous system damage; gene therapy
10/30/2001US6309856 Human MAD proteins and uses thereof
10/30/2001US6309854 Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
10/30/2001US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
1 ... 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 ... 1833